| APOE Ξ΅2/Ξ΅3 | Lower Alzheimer risk + favorable lipid profile. No E4 β MB / psilocybin / future ketamine genetically safe. |
| BDNF Val/Val (rs6265) | Normal BDNF function. Neuroplasticity baseline good β psilocybin / MB protocols genetically favored. |
| KIBRA rs17070145 T;T | Greatly enhanced episodic memory. Felt-effect journaling has unusually high signal β trust your calibration more than population reference. |
| No G6PD deficiency variant | MB methemoglobinemia risk minimal (14Γ safety margin at 0.5mg/kg oral). |
| No SLCO1B1 statin-intolerance | Statins safe if ever needed (e.g. pitavastatin for Bart angiogenesis). |
| No VKORC1 / CYP2C9 high-sensitivity | Anticoagulation tolerable, standard INR monitoring. |
| No HFE C282Y / H63D | No hemochromatosis β iron supplementation safe. |
| HLA-DRB1*1501 GG | Not high-risk MS variant β MS less likely on differential. |
| No BRCA / Lynch / MUTYH / APC / MSH / MLH hits | No additional cancer-pred panel justified. |
| Favorable lipid genetics (APOE Ξ΅2/Ξ΅3 + HDL+ cluster + low-LDL) | Don't preemptively restrict dietary fat. Still get ApoB + Lp(a) once for ground-truth baseline. |
| Gene / rsID | Genotype | Risk | Action |
|---|---|---|---|
| rs944289 (NKX2-1) | T;T | 1.69Γ thyroid Ca | Thyroid US + full panel + calcitonin. Repeat US q2y. |
| rs965513 (FOXE1) | A;G | 1.77Γ thyroid Ca (independent) | Stacks with rs944289 β same panel |
| LOXL1 rs2165241 + rs3825942 | T;T + G;G | >10Γ PEX glaucoma | Augenarzt before 40, slit-lamp + IOP + OCT, q2-3y to 50 |
| KITLG rs4474514 | A;A | >3Γ testicular Ca | Monthly self-exam (peak window 20-40y) |
| ATM rs1801516 | A;A | 2.76Γ pancreatic Ca | Watch only at 35; escalate if FH surfaces |
| rs4430796 (HNF1B) + rs11672691 (PCAT19) | A;A + G;G | 1.38Γ + 1.39Γ prostate Ca | PSA at 45 (not 50). Free-PSA + total. |
| rs1015362 | G;G | 2-4Γ sun sensitivity β melanoma | Annual Hautarzt skin check. Aggressive SPF on scalp. |
| Gene / rsID | Genotype | Risk | Action |
|---|---|---|---|
| rs4349859 (MICA, HLA-B27 tag) | A;G | HLA-B27 likely carrier | Order HLA-B27 standalone. If +: SI MRI + rheum referral. |
| rs7743761 | A;C | 4.6Γ AS risk | Same workup as HLA-B27 |
| rs6457617 | T;T | 5.2Γ rheumatoid arthritis | anti-CCP + RF + ANA panel. Rheum referral. |
| rs9268839 (HLA-DR) | A;G | 2Γ RA risk | Same panel |
| rs3738919 (ITGAV) | A;C | 1.94Γ RA | Same panel |
| IL23R rs10889677 + rs2201841 | A;C + C;T | 1.5Γ AS/Crohn's, 2Γ Graves' | Add TRAb to thyroid panel |
| ITGAM rs1143679 | A;G | 1.78Γ SLE | ANA + anti-dsDNA + C3/C4 |
| Gene | Genotype | Action |
|---|---|---|
| MTHFR C677T (rs1801133) | AG het | ~30% reduced 5,10-MTHFR. Methylated B-complex (5-MTHF + methyl-B12), not megadose. |
| MTHFR A1298C (rs1801131) | TT normal | No additional concern |
| COMT V158M (rs4680) | AG het | Moderate COMT β sticky thoughts inflammation-driven, not genetic. Avoid high-dose methyl donors during flares. |
| CYP1A2 *1F (rs762551) | AA fast | Caffeine metabolism fine. Autonomic load is the limit, not metabolism. |
| NAT2 (rs1799929) | CT intermediate | Rifampin tolerable with LFT monitoring q2 weeks during kill course. |
| GSTP1 I105V (rs1695) | AG reduced GST | NAC 1200-1800mg/day permanent β essential during mold/biotoxin/kill phases. |
| Gene | Genotype | Action |
|---|---|---|
| VDR BsmI | CC variant | Bump Vit D3 to 7000-10000 IU short-term until 25(OH)D 60-80 ng/mL, then back to 5000 IU maintenance. Always with K2-MK7 100mcg + Mg + fat. Retest q8 weeks. |
| VDR TaqI | AA variant | |
| VDR ApaI | CC variant | |
| CYP2R1 | GG slower 25-hydroxylation |
| NOS3 rs891512 | A;G | Impaired eNOS. Validates endothelial-Bart hypothesis at genotype level. L-citrulline 6g + beetroot 500ml + NAC genetically targeted. |
| 9p21 CV cluster (rs1333049 +4) | positive | 1.5Γ CAD. Aspirin microdose validated. Add Lp(a) once-in-life lab. |
| HDL+ cluster + rs174537 | favorable | Lipid genetics good β don't preemptively restrict dietary fat. |
| COL5A1 rs12722 | TT variant homo | EDS-spectrum genotype BUT phenotype-negative for hypermobility ("no hypermobility anywhere"). Vasculitis-flavored connective tissue phenotype better fit. Informs ganglion-cyst + cervical workup. |
| CILP rs2073711 | CC | Lumbar disc disease β. Inform June cervical MRI. |
| rs7639618 (COL6A4P1) | C;T | 1.45Γ osteoarthritis. Ganglion cyst + ankle clicking context. |
| rs9525638 | T;T | Weaker bone density. DEXA at 40. |
| CCR5 Ξ32 het (i3003626) | D;I | Partial Ξ32 β modified intracellular pathogen response. Permissive niche for chronic Bart. |
| IL12B C;C (rs3212227) | β | Atypical mycobacteria susceptibility. Mycobacterial coinfection differential if Bart kill stalls. |
| CCL2 rs1024611 | C;T | Chronic TB / intracellular biology. Supports Doxy+Rifa combo over Rifa-mono. |
| TLR4 D299G (rs4986790) | AA normal | Normal TLR4 β no LPS hyporesponsiveness. |
| DIO1 rs2235544 | A;A | Reduced T4βT3 conversion β metabolic-fatigue backbone. If thyroid Rx ever needed: prefer T3-containing (Armour/T3 add-on) over T4-only. |
| OXTR rs53576 | A;G | Atypical oxytocin signaling. Mild OCD-spectrum overlap. Reframe only, no protocol change. Brother schizophrenia context β sitter + integration for psychedelic sessions (already default). |
| SLC2A9 rs7442295 | ? | ~4Γ hyperuricemia. Watch on purine load β check uric acid if joint flares appear. |
| rs2395185 | ? | 2.72Γ T1D (LADA possibility). Fasting C-peptide once if labs drift. |
| DRD2 -141C (rs1799732) | II | Baseline D2 density. |
| rs4654748 (NBPF3) | C;T | 1.45 ng/mL lower B6. Already in B-complex; aim PLP upper-mid range if measured. |
| Drug | Genotype impact | Verdict |
|---|---|---|
| Methylene blue | No G6PD deficiency β methemoglobinemia margin 14Γ at 0.5mg/kg | β Genetically safe. Serotonergic interaction risk = pharmacology, not genetics. |
| Rifampin | NAT2 intermediate + no CYP issues | β Tolerable with q2-week LFTs |
| Statins / pitavastatin | No SLCO1B1 intolerance | β Safe |
| Warfarin | No VKORC1 / CYP2C9 high-sensitivity | β Standard dosing + monitoring |
| Doxycycline, atovaquone, LDN, cimetidine | No relevant variants | β Standard dosing |
| Thyroid hormone replacement (if Hashimoto progresses) | DIO1 A;A reduced T4βT3 | Prefer T3-containing (Armour / NDT / T3 add-on) |
| Pseudoephedrine / sympathomimetics | NOS3 + CV cluster | β οΈ Avoid high-dose; use less aggressive decongestants |
| Aspirin / nattokinase | NOS3 endothelial variant | β Antiplatelet approach genetically justified. Continue. |
personal/_archive/genome-2022/personal/_archive/genome-2022/promethease-report-2026-05-21.zippersonal/genome-snp-analysis-2026-05-21.md + personal/promethease-triage-2026-05-21.md + supplementary triage